3/4
08:00 am
drts
Alpha Tau Medical (DRTS) had its "neutral" rating reaffirmed by Piper Sandler. They now have a $5.00 price target on the stock.
Low
Report
Alpha Tau Medical (DRTS) had its "neutral" rating reaffirmed by Piper Sandler. They now have a $5.00 price target on the stock.
2/24
11:06 am
drts
Alpha Tau Medical (NASDAQ:DRTS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Alpha Tau Medical (NASDAQ:DRTS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
2/24
09:00 am
drts
Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer
Low
Report
Alpha Tau Medical Receives Japanese Marketing Approval for Alpha DaRT® in Unresectable Locally Advanced or Locally Recurrent Head and Neck Cancer
2/19
07:26 am
drts
Alpha Tau Medical (NASDAQ:DRTS) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
Low
Report
Alpha Tau Medical (NASDAQ:DRTS) was upgraded by analysts at Zacks Research from a "strong sell" rating to a "hold" rating.
1/29
09:00 am
drts
Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
Medium
Report
Alpha Tau Issues Letter to Shareholders: Five Concurrent Trials in the U.S. with Multiple Significant Value-Driving Milestones Ahead
1/28
09:57 am
drts
Taiho Oncology Appoints Peter Melnyk as President & Chief Executive Officer [Yahoo! Finance]
Medium
Report
Taiho Oncology Appoints Peter Melnyk as President & Chief Executive Officer [Yahoo! Finance]
1/23
03:40 am
drts
Alpha Tau Medical: Pancreatic, GBM, And Other Updates; Set Up For A Strong, Catalyst-Rich 2026 [Seeking Alpha]
Medium
Report
Alpha Tau Medical: Pancreatic, GBM, And Other Updates; Set Up For A Strong, Catalyst-Rich 2026 [Seeking Alpha]
1/21
06:19 am
drts
Alpha Tau Medical (NASDAQ:DRTS) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
Low
Report
Alpha Tau Medical (NASDAQ:DRTS) was downgraded by analysts at Zacks Research from a "hold" rating to a "strong sell" rating.
1/8
07:01 am
drts
Wall Street Breakfast Podcast: Selloff To Surge In Defense [Seeking Alpha]
Medium
Report
Wall Street Breakfast Podcast: Selloff To Surge In Defense [Seeking Alpha]
1/6
10:56 am
drts
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study [Yahoo! Finance]
Medium
Report
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study [Yahoo! Finance]
1/6
09:00 am
drts
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
High
Report
Alpha Tau Reports New Positive Results in Two Upcoming Presentations at ASCO GI 2026 Symposium Showcasing Immune-Preservation and High Disease Control in Montreal Pancreatic Cancer Alpha DaRT® Study
1/6
01:48 am
drts
Throwing Precision Darts: The Company Leading Next Evolution of Cancer Radiation [Globe and Mail, The (Toronto, Canada)]
Medium
Report
Throwing Precision Darts: The Company Leading Next Evolution of Cancer Radiation [Globe and Mail, The (Toronto, Canada)]
1/5
09:15 am
drts
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC) [Yahoo! Finance]
Low
Report
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC) [Yahoo! Finance]
1/5
09:00 am
drts
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
Medium
Report
Alpha Tau Submits First Pre-Market Approval Module to the FDA for Alpha DaRT® for the Treatment of Recurrent Cutaneous Squamous Cell Carcinoma (cSCC)
12/18
09:00 am
drts
Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference
Medium
Report
Alpha Tau to Present at the J.P. Morgan 2026 Healthcare Conference
12/10
02:28 pm
drts
Alpha Tau Medical (NASDAQ:DRTS) had its price target lowered by analysts at Citigroup Inc. from $8.00 to $7.00. They now have a "buy" rating on the stock.
Medium
Report
Alpha Tau Medical (NASDAQ:DRTS) had its price target lowered by analysts at Citigroup Inc. from $8.00 to $7.00. They now have a "buy" rating on the stock.
12/10
01:04 pm
drts
Alpha Tau Medical (NASDAQ:DRTS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Medium
Report
Alpha Tau Medical (NASDAQ:DRTS) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/9
09:00 am
drts
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
Medium
Report
Alpha Tau Successfully Treats First Patient in its U.S. Trial for Patients with Recurrent Glioblastoma at the James Cancer Hospital at The Ohio State University
12/4
09:00 am
drts
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium
Low
Report
Alpha Tau Announces Presentation of Two Alpha DaRT Pancreatic Cancer Abstracts at Upcoming 2026 ASCO GI Symposium